Skip to main content

The latest developments in oncology research

Drugmakers and, largely, the FDA argue that the medicines now being reviewed are different than the chemotherapies and blunter interventions of the past. This is having consequences for how clinical trials are being run, and for how much money drugmakers are investing in cancer R&D.

included in this trendline
  • FDA’s warning for CAR-T therapies creates new overhang
  • Merck cancer drug deal caps pharma investment influx into ‘ADC’ field
  • AbbVie joins ADC dealmaking with $10B ImmunoGen buyout
Our Trendlines go deep on the biggest trends. These special reports, produced by our team of award-winning journalists, help business leaders understand how their industries are changing.
Davide Savenije Editor-in-Chief at Industry Dive.